Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, BC, Dec. 21, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc

Related Keywords

Japan ,United States ,Ireland ,Dublin ,Vancouver ,British Columbia ,Canada ,Zymelink Auristatin ,Wilson Sonsini Goodrich Rosati ,Zymework Azymetric ,Kristin Bhavnani ,Andrean Flynn ,Diana Papove ,Kenneth Galbraith ,Asia Pacific ,Rob Iannone ,Jack Spinks ,Commission File No ,Jazz Pharmaceuticals Ireland Limited ,Zymeworks Inc ,Health Partners ,Jazz Pharmaceuticals ,Beigene Ltd ,Head Of Global Corporate Communications ,Nasdaq ,Exchange Commission ,Prnewswire Jazz Pharmaceuticals ,Corporate Communications ,Jazz Pharmaceuticals To Zymeworks ,Securities Exchange ,Wilson Sonsini Goodrich ,Caution Concerning Forward Looking ,Jazz Pharmaceutical ,Commission File ,Jazz Pharmaceutical Quarterly Report ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Media Contact ,Global Corporate Communications ,Investor Contact ,Investor Relations ,Injury Incidence ,Global Burden ,Disease Study ,Cancer Metastasis ,Jazz ,Pharmaceuticals ,Zymeworks ,Nnounce ,Onfirmed ,Advances ,Partnership ,Zanidatamab ,